Sort
25,944 grants matching “neurodegeneration”
Preclinial Development of JNK3 Inhibitors to Treat Parkinson's Disease
$1,503,665Philip Lograsso · Scripps Research Institute, The · U01 · FY2008 · NS
Genomic and Metabolomic Data Integration in a Longitudinal Cohort at Risk for Alzheimer's Disease
$1,503,432Corinne D. Engelman · University Of Wisconsin-Madison · RF1 · FY2025 · AG
In Vitro in Vivo Models of Alzheimer's Disease
$1,503,226University Of Pennsylvania · P01 · FY2004 · AG
Childhood Neurodegenerative Lysosomal Storage Disorders
$1,503,084Anil B Mukherjee · Eunice Kennedy Shriver National Institute Of Child Health & Human Development · ZIA · FY2025 · HD
Biomarkers of Catecholaminergic Neurodegeneration
$1,502,893David Goldstein · National Institute Of Neurological Disorders And Stroke · ZIA · FY2020 · NS
Age related determinants of HAND: A 12 year follow-up of CHARTER participants
$1,502,802Robert Kernachan Heaton · University Of California, San Diego · R01 · FY2019 · MH
A Caribbean Project for Clinical and Basic Neuroscience Research
$1,502,618Edmundo Nelson Kraiselburd · University Of Puerto Rico Med Sciences · U54 · FY2009 · NS
Discovery of Drugs that Modulate Neuroinflammation for the treatment of Alzheimer's Disease
$1,500,781Kevin Hodgetts · Brigham And Women'S Hospital · U01 · FY2023 · AG
Innovative Deep Phenotyping of African Americans at Risk for Alzheimers disease
$1,500,426David Loewenstein · University Of Miami School Of Medicine · R01 · FY2024 · AG
Creatine Safety, Tolerability, and Efficacy in Huntington's Disease: CREST-E
$1,500,000Steven M Hersch · Massachusetts General Hospital · U01 · FY2014 · AT
IND, FIH study and 3-month tox for PTI-125, a novel therapeutic for Alzheimer's disease
$1,500,000Lindsay H Burns · Cassava Sciences, Inc · R44 · FY2017 · AG
EXCITATORY TRANSMITTERS, MEMORY, AGING AND DEMENTIA
$1,499,255Washington University · P01 · FY2004 · AG
CTE and Posttraumatic Neurodegeneration: Neuropathology and Ex Vivo Imaging
$1,496,457Ann Carolyn McKee · Boston University Medical Campus · U01 · FY2016 · NS
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome
$1,496,403Travis Dunckley · Iluminos Therapeutics, Llc · R44 · FY2024 · NS
Biomarkers of Catecholaminergic Neurodegeneration
$1,495,643David Goldstein · National Institute Of Neurological Disorders And Stroke · ZIA · FY2019 · NS
Biomarkers of Catecholaminergic Neurodegeneration
$1,495,263David Goldstein · National Institute Of Neurological Disorders And Stroke · ZIA · FY2018 · NS
Molecular And Immunopathology Of Experimental And Clinical Ocular Diseases
$1,494,684Chi-Chao Chan · National Eye Institute · ZIA · FY2011 · EY
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease
$1,492,896Chien-Liang Glenn Lin · Ohio State University · U01 · FY2021 · AG
Development of a SYF2 antisense oligonucleotide treatment for ALS and FTD
$1,492,509Samuel V Alworth · Acurastem, Inc. · R44 · FY2023 · AG
DNA Damage and Neurodegeneration in the Aging Brain
$1,491,737Bruce A Yankner · Harvard Medical School · P01 · FY2009 · AG
AMP-AD Brain Proteomic Network Enhancement, Validation, and Translation into CSF Biomarkers
$1,491,691Allan I Levey · Emory University · U01 · FY2018 · AG
Detection of Prions
$1,491,280Byron Caughey · National Institute Of Allergy And Infectious Diseases · ZIA · FY2025 · AI
Regional, Synaptic, Cellular Modulation of Abeta Metabolism
$1,490,630David M Holtzman · Washington University · P01 · FY2018 · NS
Development of a small-molecule that enhances tripartite synapses for Alzheimers disease
$1,488,988Chien-Liang Glenn Lin · Ohio State University · U01 · FY2022 · AG
CNS sirtuins in radiation-induced vascular permeability and neurodegeneration
$1,488,434Deedee Smart · Division Of Basic Sciences - Nci · ZIA · FY2025 · CA